Embracing Complexity
Lonza’s XS™ Microbial Expression Technology Research Evaluation Agreement (REA)
Expanded to Include New Pichia Components.
Next generation antibody therapeutics are gaining traction in the pharma industry as they provide improvements over monoclonal antibodies with improved stability, increased selectivity and enhanced efficacy. With more than 60 molecules in preclinical and early clinical development with highly diverse molecule formats, no single host or vector is capable of being the best expression option for these drugs.
To address the complexity of these microbially derived novel compounds, Lonza has assembled a collection of powerful expression systems including E.coli and P. pastoris (Pichia) options to boost productivity and quality of your protein.
Pichia systems have been successful in expressing next generation antibodies. Therefore, we have expanded the Pichia offerings included in the XS™ Microbial Expression Technologies REA, providing more options to successfully express these molecules in your own development laboratories.
In addition to the expression technologies, the REA includes detailed fed-batch fermentation protocols designed to quickly create commercially-viable production strains and cGMP processes.
Advantages of Lonza’s XS™ Microbial Systems include:
| |
• Broad toolbox establishes best expression option for a diverse population of proteins
• Strong constitutive and regulated methanol-free promoters deliver high titers
• Soluble secreted production for lean DSP
• Tunable copy number increases probability of creating best production clone
• Different chromosomal integration sites supports screening of best performing clone
• Expanded Pichia systems increase the probability of expression success
|
*certain restrictions apply
|
